Floatz logo

Rta 744

Recurrent Glioblastoma Multiforme

WPD Pharmaceuticals Sp. z o.o.Phase 1/2Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

353 Active assets in the Recurrent Glioblastoma Multiforme cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Rta 744 is also rated in:

adult glioblastomaDormant
C
Indicative ·
39 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
C
Indicative ·
39 / 100
View asset →
brain neoplasmDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →